Priovant wins FDA Priority Review for brepocitinib in dermatomyositis

The U.S. Food and Drug Administration has accepted Priovant Therapeutics' New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, assigning a Prescription Drug User Fee Act target action date in the third quarter of 2026, the company said. Priovant, a subsidiary of Roivant Sciences, said it expects to launch the drug in the United States at the end of September 2026 if the agency approves the application and final labeling is agreed.

Priovant said the regulatory filing was supported by results from the Phase 3 VALOR study, which enrolled 241 patients. The company reported that brepocitinib 30 mg met the trial's primary endpoint and nine key secondary endpoints, demonstrating what it described as early and sustained benefit through Week 52. Priovant characterized VALOR as the largest and longest interventional trial in dermatomyositis to date and the first positive 52-week placebo-controlled study in the disease.

Brepocitinib is described in Priovant materials as a dual selective inhibitor of TYK2 and JAK1 that, through dual TYK2/JAK1 inhibition, "distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted, once-daily oral therapy." The company also noted ongoing development of brepocitinib in a Phase 3 program for non-infectious uveitis and positive Phase 2 data in cutaneous sarcoidosis.

The announcement underscores a potential therapeutic shift for dermatomyositis, a rare autoimmune disease in which patients suffer muscle weakness, debilitating skin disease, and frequent reliance on chronic high-dose corticosteroids. Priovant and its filings emphasized the heavy disease burden, noting that chronic steroid dependency and uncontrolled inflammation contribute to accumulated organ damage and high rates of comorbidities among patients on current standard care.

"The acceptance of our NDA for brepocitinib in dermatomyositis represents meaningful progress towards our goal of bringing a potentially transformational therapy to dermatomyositis patients who urgently need better treatment options," said Ben Zimmer, chief executive officer of Priovant. "We are committed to working closely with the FDA through their review to make this drug available for patients as quickly as possible."

Public health specialists and patient advocates have long highlighted gaps in care for rare autoimmune diseases: limited specialist access, long diagnostic delays, and uneven insurance coverage for expensive specialty therapies. If the FDA approves brepocitinib as the first targeted therapy for dermatomyositis, clinicians and health systems will face immediate questions about equitable access, coverage decisions, and capacity to identify eligible patients and monitor treatment safety.

Priovant filed the announcement in an 8-K with the Securities and Exchange Commission and distributed the press release via GlobeNewswire from Durham, North Carolina. The company provided a contact for media inquiries as Stephanie Lee at stephanie.lee@priovant.com.

Regulatory review now moves toward the Q3 2026 PDUFA target date, when the FDA must issue an action. Until full trial data and the agency's review are public, clinicians and patients will have top-line efficacy claims but limited independent detail on magnitude of benefit and safety profile. That uncertainty will shape policy and clinical planning if approval approaches, particularly around coverage rules and ensuring that marginalized communities with reduced access to specialty care are not left behind.